May 2nd 2025
The company had requested approval for its mRNA-1083 combination vaccine last year. With this setback, the company is now looking at 2026 for approval.
April 25th 2025
After delays in the review of the COVID-19 vaccine—which missed its April 1 review deadline—the agency has requested new data.
April 23rd 2025
The University of California San Francisco and Gladstone Institutes develop compounds with a 1,000,000-fold reduction in viral titers and 1000 times effective concentration in the brain.
April 21st 2025
Study of 400,000 pediatric records shows vaccine’s effectiveness in preventing Long COVID during Delta and Omicron waves.
April 17th 2025
A large study showed these SARS-CoV-2 positive groups were more prone to myocarditis, heart failure, arrhythmias, and chest pain—regardless of prior cardiovascular history or presence of congenital heart disease (CHD).
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Health Care Workers Hospitalized with COVID-19 May Have Lower Risks
February 8th 2021Health care workers hospitalized with COVID-19 showed no greater risk than the general public for mechanical ventilation or death, and may actually have less risk of ICU admission and shorter hospital stays, a new study found.
Read More
Social Disadvantages Associated with Higher Rates of COVID-19 Cases, Death
February 5th 2021US counties that scored higher on the Social Vulnerability Index, which includes such factors as poverty, unemployment and education, saw higher incidence rates of COVID-19 cases and deaths, a University of Michigan study found.
Read More
FDA Updates its EUA for Convalescent Plasma
February 5th 2021The agency limited it Emergency Use Authorization (EUA) for the COVID-19 therapy to the use of high titer COVID-19 convalescent plasma only for the treatment of hospitalized patients early in the disease. FDA is no longer authorizing the use of low-titer plasma in its EUA due to a lack of efficaciousness in further studies.
Read More
2 Commerce Drive
Cranbury, NJ 08512